Biogen Idec Aims to Regenerate Damaged Nerves, Crack Multi-Billion Dollar Market Xconomy - Podcasts powered by Odiogo

Biogen Idec’s scientists have a vision for regenerative medicine, and it has nothing to do with what’s been written and said about embryonic stem cells.
Deep in Biogen’s pipeline, on the verge of entering clinical trials, are a pair of regenerative medicines that the company hopes will become trailblazers in the world of neurological diseases. [...]Click here to play